1281 INCIDENCE OF BLADDER CANCER AS A SECONDARY MALIGNANCY IN PATIENTS TREATED WITH RADIATION FOR CERVICAL CANCER

Abstract

You have accessJournal of UrologyBladder Cancer: Detection and Screening1 Apr 20121281 INCIDENCE OF BLADDER CANCER AS A SECONDARY MALIGNANCY IN PATIENTS TREATED WITH RADIATION FOR CERVICAL CANCER Janet Baack Kukreja, Emelian Scosyrev, Edward Messing, and Guan Wu Janet Baack KukrejaJanet Baack Kukreja Rochester, NY More articles by this author , Emelian ScosyrevEmelian Scosyrev Rochester, NY More articles by this author , Edward MessingEdward Messing Rochester, NY More articles by this author , and Guan WuGuan Wu Rochester, NY More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2012.02.1613AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES The risk of bladder cancer attributable to radiation exposure in women treated with external beam radiation therapy (EBRT) with or without brachytherapy (BT) for cervical cancer has not been evaluated. The main objectives of this study were to examine the incidence of bladder cancer following radiotherapy for cervical cancer. METHODS Data for this study was obtained from the Surveillance, Epidemiology and End-Results (SEER) Program. Women diagnosed with cervical cancer as their first malignant primary during years 1980-2005 who had follow-up data and were managed either without radiotherapy or with EBRT +/− BT were included in the analyses (n=26,528). Occurrence of bladder cancer over time was summarized with counts and person-time incidence rates (counts divided by person-years of observation). Rate contrasts were expressed as differences and ratios. Age-adjustment was performed by direct standardization to the age-specific person-time distribution of all patients included in the analyses. RESULTS A total of 12,876 women in the study cohort received EBRT +/− BT as treatment for cervical cancer. The mean age at cervical cancer diagnosis was 55.1 years. After 90,403 person-years of follow-up. The crude incidence rate was 9.6 per 10,000 person-years (95%CI: 7.6-11.6) and the age-standardized incidence rate was 7.3 per 10,000 person-years (95%CI: 5.6-9.0). The control group included 13,652 women whose cervical cancer was managed without radiotherapy. The mean age at cervical cancer diagnosis was 45.3 years. The crude incidence rate was 2.3 per 10,000 person-years (95% CI: 1.6-3.0) and the age standardized incidence rate was 3.0 per 10,000 person-years (95%CI: 2.0-4.1). After age-adjustment, the rate of incident bladder cancer in women treated with EBRT +/− BT was 2.4 times greater than the rate in women managed without radiation (95%CI: 1.6-3.6). Assuming that the current estimates represent causal effects of radiation exposure, on average 4.3 incident bladder cancer cases per 10,000 person-years of follow-up could be attributed to radiation in this study cohort (95%CI: 2.4-6.2). CONCLUSIONS EBRT +/− BT administered for cervical cancer may increase the subsequent risk of bladder cancer by more than two-fold. In this cohort of women, 4.3 incident bladder cancer cases per 10,000 person-years of follow-up could be attributed to radiation. © 2012 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 187Issue 4SApril 2012Page: e519 Advertisement Copyright & Permissions© 2012 by American Urological Association Education and Research, Inc.MetricsAuthor Information Janet Baack Kukreja Rochester, NY More articles by this author Emelian Scosyrev Rochester, NY More articles by this author Edward Messing Rochester, NY More articles by this author Guan Wu Rochester, NY More articles by this author Expand All Advertisement Advertisement Loading ...